Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 9, Number 7—July 2003

Research

Amoeba-Resisting Bacteria and Ventilator-Associated Pneumonia

Bernard La Scola*, Ioanna Boyadjiev*†, Gilbert Greub*, Atieh Khamis*, Claude Martin†, and Didier Raoult*†Comments to Author 
Author affiliations: *Unité des Rickettsies, Marseille, France; †Hôpital Nord, Marseille, France

Main Article

Table 6

Clinical characteristics of patients with or without seroconversion to one of the amoeba-associated bacteriaa

Clinical characteristics Seroconversion
(N=12) No seroconversion
(N=18) p
value
Demographic data
Median age in y (IQR) 35 (25–43) 24 (21–52) 0.85
Male (%) 10 (83.3) 15 (83.3) 1
Risk and potential confounding factors
Underlying disease (%) 2 (16.6) 3 (16.6) 1
Circulation injury (%) 9 (75) 14 (77.8) 1
Median APACHE IIa score (IQR) 21 (14–4) 23 (16–34) 0.12
Intubation in ICU (%) 8 (66.6) 7 (38.9) 0.26
Median hospitalization days (IQR) 25 (19–41) 17 (10–23) 0.094
Median intubation duration in days (IQR) 11 (7–20) 11 (7–20) 0.8
Median number of serum samples (IQR) 3 (3–5) 3 (2–4) 0.12
Clinical data
VAP (%) 10 (83.3) 7 (38.9) 0.026
Unexplained VAP (%) 6 (50) 2 (11.1) 0.034
Fever > 38.5 °C (%) 12 (100) 17 (84.4) 1
Unexplained fever (%) 7 (58.3) 11 (39.3) 0.27
SIRS (%) 12 (100) 11 (61.1) 0.024
Unexplained SIRS (%) 7 (58.3) 3 (14.3) 0.045
Death (%) 2 (16.7) 8 (44.4) 0.23
Paraclinical data
Leukocytes > 12 g/L (%) 12 (100) 14 (77.8) 0.13
Platelets > 500 g/L (%) 5 (41.7) 6 (33.3) 0.7
PCR detection of ARB in BAL samples(%) 2 (17) 0 0.15

aIQR, interquartile range; VAP, ventilator-associated pneumonia; SIRS, Systemic Inflammatory Response Syndrome; APACHE II, Acute Physiology and Chronic Health Evaluation II; PCR, polymerase chain reaction; ARB, angiotensin receptor blockers; BAL, bronchoalveolar lavage samples; bold p values are those that are significant (<0.05).

Main Article

TOP